JHVE photos
U.S. stock futures opened slightly lower on Friday, a day after Wall Street’s rally stalled after another historic milestone. Here are some stocks to watch on Friday:
- FactSet Research Systems (FDS) Shares get about 4% In premarket trading, the company reported strong quarterly results that overshadowed a cut in annual revenue guidance. FactSet in Norwalk, Connecticut (flight data system) creates data and software solutions for investment professionals that provide them with financial data and analytics. set of facts (flight data system) Q3 2024 Organic Annual Subscription Value (ASV) plus Professional Services Increase 5% year over year to $2.22B. ASV represents forward-looking revenue for the next 12 months for all subscription services currently offered to customers.
- CarMax (KMX) stock holds slight gains ahead of opening bell, ends with Up nearly 1%. The used car retailer announced top- and bottom-line results for the first quarter of 2025 despite declines in retail used vehicle sales and comparable store used vehicle sales. CarMax (KMX) purchased 314,000 vehicles from consumers and dealers this quarter, down 8.6% year over year. “I’m encouraged by the trends we saw in the first quarter, including continued year-over-year price declines, improving vehicle value stability and continued growth in upper-funnel demand,” said CarMax (KMX) CEO Bill Nash.
- Spirit AeroSystems (SPR) Stock Up about 5% Reuters previously reported that the company and aircraft manufacturer Boeing (BA) were close to reaching an agreement after months of negotiations. Boeing ( BA ) is making progress on reacquiring Spirit ( SPR ) after the parts supplier entered into discussions with Airbus ( OTCPK:EADSF ) ( OTCPK:EADSY ) over a possible transatlantic deal, Reuters reported, citing people familiar with the matter. Substantial progress has been made in separate negotiations on the demerger. Spirit (SPR) is Boeing Co.’s (BA) largest parts supplier. If the deal goes through, the company would return to Boeing ( BA ) following its 2005 spinoff.
- Gilead Sciences (GILD) Stock Add more than 3% in pre-market trading after a sharp 8.5% jump in the previous session. Gilead (GILD) said Thursday that an interim analysis of a late-stage trial showed that its lenacapavir treatment showed superiority to Truvada in preventing HIV infection in cisgender women. Gilead added that an independent data monitoring committee recommended stopping the blinded phase of the trial and offering open-label lenapavir to all subjects.
